Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Amiloride

Classification: B

Drug products: Amiloferm®, Amiloferm® mite, Amilorid HCL, Amilorid Mylan, Amiloride, Amiloride Hydrochloride, Midamor, Modamide, Moduretic, Moduretic®, Moduretic® mite, Normorix, Normorix mite, Sparkal®, Sparkal® mite

ATC code: C03DB01, C03EA01

Substances: amiloride, amiloride hydrochloride anhydrous, amiloride hydrochloride dihydrate

Summary

Controlled studies on differences between men and women on effect, safety and pharmacokinetics for amiloride are lacking.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of amiloride have been found.

Dosing

No studies with a clinically relevant sex analysis regarding the dosing of amiloride have been found.

Effects

No conclusive studies with a clinically relevant sex analysis regarding the effects of amiloride have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of amiloride have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A large British randomized, placebo-controlled, single-blind trial compared treatment with hydrochlorothiazide plus amiloride and atenolol in hypertensive older adults (in total 1836 men, 2560 women). Number of deaths from cancer among patients taking diuretic was higher in men than women (0.7% of men 0.3% of women on diuretics compared to 0.5% of men and 0.6% of women with placebo) [1]. These results have unclear relevance today. The cancer mortality rates in UK have fallen by 19% for women and 29% for men between 1990-2016 [2].

Updated: 2020-08-28

Date of litterature search: 2019-03-11

References

  1. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results . British Medical Journal. 1992;304:405-412.
  2. Cancer Research UK. Cancer Stats: Cancer Statistics for the UK. Cancer Research UK [www]. [cited 2019-03-28]. länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson